Transient Anti-Glutamic Acid Decarboxylase (GAD) Antibody Positivity and Insulin Secretion Reduction After IVIg in Type 2 Diabetes Mellitus. [PDF]
Nakashima H+6 more
europepmc +1 more source
What's New? Liver function decreases with age, affecting the metabolism of many chemotherapy drugs. For older cancer patients, however, a standardized liver status screening method is lacking. Here, Fibrosis‐4 (FIB‐4) score was investigated for its utility as a non‐invasive method in predicting treatment toxicity and mortality in cancer patients age 70
Victoire de Salins+14 more
wiley +1 more source
Reply to comment on "Association between self-reported weight loss and new long-term care insurance certifications: A 9-year Japanese older adult cohort study". [PDF]
Katayose R, Okura M, Arai H, Ogita M.
europepmc +1 more source
Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao+6 more
wiley +1 more source
Clinical efficacy of oxidized regenerated cellulose powder in perioperative blood management in direct anterior total hip arthroplasty. [PDF]
Kaneko T, Hayakawa K, Miyazaki T.
europepmc +1 more source
Integrative omics approaches to uncover liquid‐based cancer‐predicting biomarkers in Lynch syndrome
What's New? Lynch syndrome (LS) significantly increases lifetime cancer risk, necessitating innovative approaches for risk stratification. Current risk assessment methods, however, fail to integrate data from different biological systems, which may be influenced by lifestyle factors.
Minta Kärkkäinen+9 more
wiley +1 more source
Correction to: Association between cognitive reserve proxies and frailty phenotype: data from UK Biobank. [PDF]
Lorenzo-Lopez L+11 more
europepmc +1 more source
Anti‐Her2 therapy patterns in metastatic breast cancer—Real‐world data suggest undertreatment
What's New? Although human epidermal growth factor 2‐positive (HER2+) breast cancer is an aggressive malignancy, significant survival benefits are possible with targeted anti‐HER2 therapies. Whether these therapies are used as recommended, however, is unknown. Here, the authors investigated data from population‐based registries in Norway to assess anti‐
Kathrine F. Vandraas+9 more
wiley +1 more source